Sitravatinib, Multikinase inhibitor / Immuno-oncology agent (TBI4826)
$90.00 – $360.00
Multikinase inhibitor / Immuno-oncology agent
SKU | Stock | SIZE (mg) | Price | Quantity | ||
---|---|---|---|---|---|---|
TBI4826-5MG | Yes | 5 MG | $90.00 | |||
TBI4826-25MG | Yes | 25 MG | $360.00 |
- Description
- Terms
- Additional information
- Documents
- Reviews (0)
Description
Product Details
Formal Name: 1-N’-[3-Fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Alternate Names: MGCD516
Molecular Formula: C33H29F2N5O4S
Formula Weight: 629.68
CAS Number: 1123837-84-2
Purity: >98%
Formulation: powder
Solubility: Soluble in DMSO (up to at least 25 mg/ml) or in Ethanol (up to at least 25 mg/ml)
Storage: -20°C
Stability: ≥ 1 year.
Applications
Multikinase inhibitor / Immuno-oncology agent
Functions
Sitravatinib is a broad spectrum receptor tyrosine kinase inhibitor. Its targets include Axl, c-Met, PDGFR, VEGFR, Ephrin receptor family, and FLT3 among others at nanomolar levels. Sitravatinib has been tested in mouse models of sarcoma and showed better efficacy than both imatinib and crizotinib. Because of its unique kinase inhibition profile (especially that of TAM receptors), it has been used to restore response to anti-PD-1 therapy (nivolumab) in NSCLC patients. Sitravatinib was able to significantly alter the immunosuppressive tumor microenvironment in three preclinical tumor models to enhance the effects of PD-1 blockade therapy.
Application Procedures
First dissolved in DMSO (up to at least 25 mg/ml) or in Ethanol (up to at least 25 mg/ml), then diluted to aqueous buffer. Solutions in DMSO or ethanol may be stored at -20°C for up to 1 month.
Additional information
SIZE (mg) | 25 MG, 5 MG |
---|
Be the first to review “Sitravatinib, Multikinase inhibitor / Immuno-oncology agent (TBI4826)”
You must be logged in to post a review.
Reviews
There are no reviews yet.